On July 21, 2026, HeartCare-B (HKEX: 06609) released its interim profit forecast for the year 2026.

The company anticipates its operating revenue for the first half of 2026 to be no less than RMB 2.8 billion, representing an increase of over 50% compared to the same period in 2025.

It expects to achieve a net profit of no less than RMB 600 million and an adjusted net profit of no less than RMB 700 million, the latter marking a year-on-year growth exceeding 100%, indicating a further enhancement in profitability.

Revenue Surge and Core Business Momentum

The period saw the company persistently advancing its three core business segments: ischemic stroke, hemorrhagic stroke, and vascular closure.

The clinical recognition and market penetration of its core products continued to improve, driving steady growth in end-user demand.

Concurrently, the company expanded its hospital coverage network and broadened the application scope of its products, contributing to the rapid revenue growth of its core businesses.

Enhanced Profitability and Operational Efficiency

During the reporting period, the company continued to upgrade its business structure, transitioning from a 1.0 stage driven by access products to a 2.0 stage led by innovative therapeutic products.

The revenue contribution from high-value innovative products increased, leading to an improvement in the overall gross margin compared to the previous year.

Simultaneously, the company strengthened refined operations management and improved resource allocation efficiency, resulting in a rapid increase in adjusted net profit.

The rapid growth in operating performance is a significant outcome of the company's efforts to solidify its technological capabilities, optimize its product portfolio, and enhance operational quality, reflecting a continuous improvement in its operational standards and development resilience.

Looking ahead, HeartCare-B will remain focused on the clinical needs within the neurointerventional field, adhere to an innovation-driven development strategy, accelerate the commercialization of innovative products, continuously enhance its R&D innovation and market expansion capabilities, promote the clinical application of more innovative medical devices, and create long-term, sustainable value for shareholders and society.